A practical reference on Reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-24. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Protactinium (91Pa) has no stable isotopes. As 231Pa occurs in usable quantity, and comprises virtually all of the element, it defines the standard atomic weight. Thirty radioisotopes of protactinium have been characterized, ranging from 210Pa to 239Pa. The most stable isotopes are 231Pa with a half-life of 32,700 years, 233Pa with a half-life of 26.975 days, and 230Pa with a half-life of 17.4 days. All of the remaining radioactive isotopes have half-lives less than 1.6 days, and the majority of these have half-lives less than 1.8 seconds. This element also has five meta states, 217mPa (t1/2 1.15 milliseconds), 220m1Pa (t1/2 = 308 nanoseconds), 220m2Pa (t1/2 = 69 nanoseconds), 229mPa (t1/2 = 420 nanoseconds), and 234mPa (t1/2 = 1.16 minutes). The only naturally occurring isotopes are 231Pa, 233Pa, 234Pa, and 234mPa. The first occurs as an intermediate decay product of 235U, the second of (rare) 237Np, and the last two as intermediate decay products of 238U. 231Pa dominates solely because of its longer life. The primary decay mode for protactinium isotopes lighter than (and including) the most stable isotope 231Pa is alpha decay to isotopes of actinium, except 228Pa to 230Pa, which primarily decay by electron capture to isotopes of thorium. The primary mode for the heavier isotopes is beta minus (β−) decay to isotopes of uranium.
== Contraindications == Zopiclone causes impaired driving skills similar to those of benzodiazepines. Long-term users of hypnotic drugs for sleep disorders develop only partial tolerance to adverse effects on driving, with users of hypnotic drugs even after one year of use still showing an increased motor vehicle accident rate. Patients who drive motor vehicles should not take zopiclone as there is a significantly increased risk of accidents in zopiclone users. Zopiclone induces impairment of psychomotor function. Driving or operating machinery should be avoided after taking zopiclone as effects can carry over to the next day, including impaired hand-eye coordination. A double-blind study on the effect on performance of several hypnotic medications, relevant to military personnel who may have to be awakened to carry out duties, found that drugs listed in increasing order of performance impact duration were melatonin (with no impact), zaleplon, temazepam, and zopiclone. The effects on serial reaction time (SRT), logical reasoning (LRT), serial subtraction (SST), and multitask (MT) were measured. For zaleplon (10 mg), zopiclone (7.5 mg) and temazepam (15 mg) respectively the times to recover normal performance for SRT were 3.25, 6.25, and 5.25 hours; for LRT 3.25, >6.25, and 4.25 hours; for SST 2.25, >6.25, and 4.25 hours; and for MT 2.25, 4.25, and 3.25 hours. The study did not consider the effectiveness of the drugs on sleep.
== Essential amino acids in plant food == Essential amino acids (EAAs) are the amino acids required by an organism for building proteins but which cannot be synthesized by the organism itself. As such it is essential that these amino acids be supplied by the organism's diet. In case of humans there are 9 EAAs: histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine. EAAs are provided in both animal and plant-based food. The EAAs in plants vary greatly due to the vast variation in the plant world and, in general, plants have much lower content of proteins than animal food. Some plant-based foods contain few or no EAAs, e.g. some sprouts, mango, pineapple, lime and melon. On the other hand, nuts, seeds, beans and peas contain EAAs in significant quantity. The following table shows the composition of EAAs in selected plant foods as well as recommended dietary allowances.(RDA)
Erythritol (, US: ) is an organic compound, the naturally occurring achiral meso four-carbon sugar alcohol (or polyol). It is the reduced form of either D- or L-erythrose and one of the two reduced forms of erythrulose. It is used as a food additive and sugar substitute. It is synthesized from corn using enzymes and fermentation. Its formula is C4H10O4, or HO(CH2)(CHOH)2(CH2)OH. Erythritol is 60–70% as sweet as table sugar. However, erythritol is almost completely noncaloric and does not affect blood sugar or cause tooth decay. Japanese companies pioneered the commercial development of erythritol as a sweetener in the 1990s.
Sources: en.wikipedia.org
=== Drug demand and decriminalization === According to former Presidents Fernando Henrique Cardoso of Brazil, Ernesto Zedillo of Mexico and César Gaviria of Colombia, the United States-led drug war is pushing Latin America into a downward spiral; Cardoso said in a conference that "the available evidence indicates that the war on drugs is a failed war". The panel of the Latin American Commission on Drugs and Democracy commission, headed by Cardoso, stated that the countries involved in this war should remove the "taboos" and re-examine the anti-drug programs. Latin American governments have followed the advice of the U.S. to combat the drug war, but the policies have had little effect. The commission made some recommendations to United States President Barack Obama to consider new policies, such as decriminalization of marijuana and to treat drug use as a public health problem and not as a security problem. The Council on Hemispheric Affairs states it is time to consider drug decriminalization and legalization. RAND studies released in the mid-1990s found that using drug user treatment to reduce drug consumption in the United States is seven times more cost-effective than law enforcement efforts alone, and it could potentially cut consumption by a third. In 2011, the Obama administration requested approximately $5.6 billion to support demand reduction. This includes a 13% increase for prevention and almost a 4% increase for treatment. The overall 2011 counter-drug request for supply reduction and domestic law enforcement is $15.5 billion, with $521.1 million in new funding.
== S == SAII – Solvent-assisted ionization inlet SELDI – Surface-enhanced laser desorption/ionization SESI – Secondary electrospray ionization SHRIMP – Sensitive high-resolution ion microprobe SIFT – Selected ion flow tube SILAC – Stable isotope labelling by amino acids in cell culture SIM – Selected ion monitoring SIMS – Secondary ion mass spectrometry SIR – Selected ion recording SNMS – Secondary neutral mass spectrometry SRM – Selected reaction monitoring SWIFT – Stored waveform inverse Fourier transform SID – Surface-induced dissociation SIR – Surface-induced reaction SI – Surface ionization SORI – Sustained off-resonance irradiation
"A Fresh Approach". Trains. February 2010. Archived from the original on 2008-10-17. "Massive Trains". Treehugger (A Discovery Company). November 2009. Archived from the original on 2009-12-29. Retrieved 2009-12-23. "Washington state Government presentation" (PDF). c. 2002. Archived from the original (PDF) on 2010-11-04. Retrieved 2010-10-05.
=== The University of California === In 2018, King published the book, The University of California: Creating, Nurturing, and Maintaining Academic Quality in a Public University Setting. The book examines in depth the factors that have contributed to the academic success of University of California. He has made the book freely available through eScholarship.
Between 1634 and 1637, the enthusiasm for the new flowers in the Netherlands triggered a speculative frenzy now known as the tulip mania, the first recorded speculative bubble in history, that eventually led to the collapse of the market three years later. Tulip bulbs had become so expensive that they were treated as a form of currency, or rather, as futures, forcing the Dutch government to introduce trading restrictions on the bulbs. The 'Semper Augustus' was the most expensive tulip during the 17th-century tulip mania. At the height of 'Tulip mania' this tulip was even sold for 10.000 guilders (equivalent to approx. €130.000 in 2024). After seeing the tulip in the garden of Dr. Adriaan Pauw, a director of the Dutch East India Company, Nicolas van Wassenaer wrote in 1624 that "The colour is white, with carmine on a blue base, and with an unbroken flame right to the top". The 'Semper Augustus' was actually not a tulip variety, but rather a tulip affected by the tulip mosaic virus. With limited specimens in existence at the time and most owned by Pauw, his refusal to sell any flowers, despite wildly escalating offers, is believed by some to have sparked the mania. Around this time, the ceramic tulipiere was devised for the display of cut flowers stem by stem. Vases and bouquets, usually including tulips, often appeared in Dutch still-life painting. To this day, tulips are associated with the Netherlands, and the cultivated forms of the tulip are often called "Dutch tulips". The Netherlands has the world's largest permanent display of tulips at the Keukenhof.
Sources: en.wikipedia.org
=== Physiological === The peripheral actions of oxytocin mainly reflect secretion from the pituitary gland. The behavioral effects of oxytocin are thought to reflect release from centrally projecting oxytocin neurons, different from those that project to the pituitary gland, or that are collaterals from them. Neurons express oxytocin receptors in many parts of the brain and spinal cord, including the amygdala, ventromedial hypothalamus, septum, nucleus accumbens, and brainstem. The distribution differs markedly between species. Furthermore, the distribution of these receptors changes during development and has been observed to change after parturition in the montane vole.
Most magnetic nanoparticle applications in clinical settings are used for cancer therapies. Magnetic nanoparticles have the ability to target the specific locus of the tumor, use a decreased amount of drug to treat the tumor, and result in decreased off-target effects of the drug. The most common method of introducing magnetic nanoparticles into the body is through intravenous injection; from the site of injection, the nanoparticles travel through the bloodstream. They eventually migrate to the target site with the use of external or implanted magnetic forces. A pH/magnetic field dual responsive drug loaded nanomicell was developed for targeted magnetothermal synergistic chemotherapy of cancer. In this drug delivery system, after the drug reaches the target site and tumor cell uptake is complete, an external magnetic field is applied causing a magnetothermal effect, raising the tumor cells' temperature and further promoting drug uptake. This nanocarrier system aims to improve drug stability, control drug release, and improve tumor targeting efficacy. This approach has shown increased treatment efficacy over traditional chemotherapy and has not demonstrated any noticeable biotoxicity. Cardiovascular disease treatment presents as another application of magnetic nanoparticle drug delivery. Atherosclerosis cardiovascular disease is a buildup of plaque in the inner lining of the arteries, and there are models on how magnetic nanoparticle drug delivery could be used as a treatment.
== Patents == U.S. patent 3,740,385 "N-Terminal Derivatives of Secretin", filed May 1970, issued June 1973 U.S. patent 4,199,512 "Compounds for alleviating hypertension", filed September 1978, issued April 1980 U.S. patent 4,154,935 "Halogen substituted mercaptoacylamino acids", filed September 1978, issued May 1978 U.S. patent 4,241,076 "Halogenated substituted mercaptoacylamino acids", filed May 1979, issued December 1980 U.S. patent 4,339,600 "Compounds for alleviating angiotensin related hypertension", filed February 1978, issued July 1982 U.S. patent 4,722,810 "Enkephalinase inhibitors", filed August 1986, issued February 1988
Naltrexone and its active metabolite 6β-naltrexol are competitive antagonists of the opioid receptors. Naltrexone is specifically an antagonist preferentially of the μ-opioid receptor (MOR), to a lesser extent of the κ-opioid receptor (KOR), and to a much lesser extent of the δ-opioid receptor (DOR). However, naltrexone is not actually a silent antagonist of these receptors but instead acts as a weak partial agonist, with Emax values of 14 to 29% at the MOR, 16 to 39% at the KOR, and 14 to 25% at the DOR in different studies. In accordance with its partial agonism, although naltrexone is described as a pure opioid receptor antagonist, it has shown some evidence of weak opioid effects in clinical and preclinical studies. By itself, naltrexone acts as an antagonist or weak partial agonist of the opioid receptors. In combination with agonists of the MOR such as morphine however, naltrexone appears to become an inverse agonist of the MOR. Conversely, the naltrexone remains a neutral antagonist (or weak partial agonist) of the KOR and DOR. In contrast to naltrexone, 6β-naltrexol is purely a neutral antagonist of the opioid receptors. The MOR inverse agonism of naltrexone, when it is co-present with MOR agonists, may in part underlie its ability to precipitate withdrawal in opioid-dependent individuals. This may be due to suppression of basal MOR signaling via inverse agonism. Occupancy of the opioid receptors in the brain by naltrexone has been studied using positron emission tomography (PET).
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.